Sequence-dependent real-world efficacy of anti-TNF antibodies and vedolizumab in ulcerative colitis: a propensity score-weighted cohort study

Abstract Background Previous exposure to advanced treatments for IBD is considered to reduce remission rates in further therapy lines and optimal treatment sequences remain to be established. Methods We performed a retrospective propensity score-weighted cohort study including a total of 219 patients (281 therapy lines) with ulcerative colitis (UC) to compare the efficacy of first-line vedolizumab with second-line vedolizumab after previous anti-TNF and vice versa. Results While second-line vedolizumab after first-line anti-TNF resulted in clearly lower rates of clinical and steroid-free remission after 52 weeks compared with first-line vedolizumab, no statistically significant reduction in clinical or steroid-free remission was detected for second-line anti-TNF after first-line vedolizumab compared with first-line anti-TNF. Conclusion Exposure to vedolizumab was not associated with a statistically significant reduction in the effectiveness of subsequent anti-TNF antibodies in second-line therapy of UC, whereas prior exposure to anti-TNF antibodies was associated with a statistically significant reduction in the effectiveness of subsequent vedolizumab. These findings support considering vedolizumab as a first-line treatment option, although direct comparisons of treatment sequences are needed to determine the optimal treatment strategy.

Authors

Institutions

Publication Details

Journal
BMC Gastroenterology
Published
2026-11-14
DOI
https://doi.org/10.1186/s12876-026-05560-4
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sequence-dependent real-world efficacy of anti-TNF antibodies and vedolizumab in ulcerative colitis: a propensity score-weighted cohort study

Tanja Martina Müller, Sophie Haberkamp, Markus Friedrich Neurath, Sebastian Zundler et al.
BMC Gastroenterology
Inflammatory Bowel Disease
article

Sequence-dependent real-world efficacy of anti-TNF antibodies and vedolizumab in ulcerative colitis: a propensity score-weighted cohort study

Tanja Martina Müller, Sophie Haberkamp, Markus Friedrich Neurath, Sebastian Zundler, Sebastian Schramm, Rachel Rouse-Merkel, Raja Atreya, Fabienne Assel
article en

Abstract

Abstract Background Previous exposure to advanced treatments for IBD is considered to reduce remission rates in further therapy lines and optimal treatment sequences remain to be established. Methods We performed a retrospective propensity score-weighted cohort study including a total of 219 patients (281 therapy lines) with ulcerative colitis (UC) to compare the efficacy of first-line vedolizumab with second-line vedolizumab after previous anti-TNF and vice versa. Results While second-line vedolizumab after first-line anti-TNF resulted in clearly lower rates of clinical and steroid-free remission after 52 weeks compared with first-line vedolizumab, no statistically significant reduction in clinical or steroid-free remission was detected for second-line anti-TNF after first-line vedolizumab compared with first-line anti-TNF. Conclusion Exposure to vedolizumab was not associated with a statistically significant reduction in the effectiveness of subsequent anti-TNF antibodies in second-line therapy of UC, whereas prior exposure to anti-TNF antibodies was associated with a statistically significant reduction in the effectiveness of subsequent vedolizumab. These findings support considering vedolizumab as a first-line treatment option, although direct comparisons of treatment sequences are needed to determine the optimal treatment strategy.

BMC GastroenterologyVol. 26(1)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universitätsklinikum Erlangen (DE)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon